AbCellera BiologicsABCL +10.81%59 Current Ratio is 14.05 as of Mar. 2026, which is 50% above its 10-year median of 9.34. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, AbCellera Biologics ranks better than 85.52% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. AbCellera Biologics's current ratio for the quarter that ended in Mar. 2026 was 14.05.
AbCellera Biologics has a current ratio of 14.05. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for AbCellera Biologics's Current Ratio or its related term are showing as below:
ABCL'
s Current Ratio Range Over the Past 10 Years
Min: 1.6 Med: 9.34 Max: 16.22
Current: 14.05
During the past 8 years, AbCellera Biologics's highest Current Ratio was 16.22. The lowest was 1.60. And the median was 9.34.
ABCL's Current Ratio is ranked better than 85.52% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs ABCL: 14.05
AbCellera Biologics (NAS:ABCL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
AbCellera Biologics Current Ratio Related Terms
AbCellera Biologics Current Ratio Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABCL vs SRPT, RAPP, RXRX: Current Ratio Comparison
For the Biotechnology subindustry, AbCellera Biologics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Current Ratio distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Current Ratio of 14.05 as of Mar. 2026. This is 50% above median its historical median of 9.34. Over the past decade, AbCellera Biologics' Current Ratio has ranged from 1.60 to 16.22. According to the industry distribution chart, AbCellera Biologics ranks #205 out of 1416 companies in the Biotechnology industry, placing it in the top 14.5%.
Is AbCellera Biologics' Current Ratio too high?
AbCellera Biologics' current Current Ratio of 14.05 is 50% above median its 10-year median of 9.34. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 16.22. The Biotechnology industry median Current Ratio is 3.89. AbCellera Biologics' value of 14.05 is 261.6% above this industry median. Based on the distribution chart, AbCellera Biologics ranks #205 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Current Ratio compare to SRPT and RAPP?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #205 out of 1416 companies for Current Ratio. This places AbCellera Biologics in the top 15% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. AbCellera Biologics' value of 14.05 is 261.6% above this benchmark. Historically, AbCellera Biologics' own Current Ratio has ranged from 1.60 to 16.22 over the past decade. While the company's 10-year median is 9.34 vs. the industry median of 3.89, AbCellera Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Current Ratio of 14.05 is 261.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Current Ratio is 14.05, which is 50% above median its own 10-year median of 9.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.38 — trading 31.3% above its estimated fair value. The current Current Ratio is 14.05, which is 50% above median its 10-year median of 9.34 and 261.6% above the Biotechnology industry median of 3.89. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Current Ratio is 14.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.38 is trading 31.3% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Current Ratio: 14.05 (50% above median its 10-year median of 9.34)
GF Value™: $5.62 vs. price of $7.38 (31.3% above fair value)
Industry Position: 261.6% above the Biotechnology median (#205 of 1416)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score
Get the complete analysis for ABCL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
